Somnox 2 turns a familiar bedtime idea—following a gentle breathing rhythm—into something you can hold. Its appeal is easy to understand when counting breaths feels like another task. Whether the device improves sleep is a separate question. This review examines published studies and manufacturer documentation; it includes no hands-on testing.
What the device asks you to do
The manufacturer’s instructions describe a companion whose surface expands and contracts, with optional soothing audio. The app changes breathing settings and sounds, while a physical button starts a session without opening the app. These are practical design choices: a person can follow a physical rhythm without continuously looking at a screen.
Somnox’s FAQ says the simulated breathing can help a user relax and fall asleep. That is the company’s proposed benefit. A comfortable ritual, a change in perceived stress and a demonstrated treatment effect each require their own evidence.
What the September trial adds
A September 30, 2026 randomized crossover trial analyzed 40 adults with sleep problems and worry-related stress; 90% were female. Participants spent six weeks using Somnox and six weeks without it, in randomized order. Their Sleep Condition Indicator scores averaged 4.22 points higher during device use; higher scores indicate fewer sleep difficulties. Only 27.5% improved by at least seven points, the study’s threshold for reliable clinical change. Perceived stress also improved; quality-of-life comparisons were not significant.
The limits matter. Outcomes were self-reported, the comparison involved no device, and a one-day break was likely insufficient to separate the periods; carryover effects occurred. The design cannot isolate breathing guidance from expectations or the attention involved in a bedtime routine. A separate analysis of the first period supported the sleep finding but did not find a significant stress difference.
The researchers reported regional public funding and no commercial conflicts; Somnox supplied the devices.
The earlier trials complicate the picture
In an earlier randomized study of 44 adults with insomnia, three weeks using a Somnox sleep robot did not significantly outperform a waiting-list comparison on insomnia severity. Sleep diaries and wrist activity monitoring also showed no significant between-group effects. That study concerned an earlier device intervention, so it should not be presented as an identical test of every current feature. It does challenge the idea that a breathing robot’s sleep benefit can simply be assumed.
A 2025 feasibility trial tested Somnox 2 in 31 adults with PTSD and impaired sleep. Both groups received a robot; only one simulated breathing. Distress improved more with breathing simulation, but sleep quality, PTSD symptoms and wellbeing did not improve significantly more than in the control group. The study was primarily designed to establish feasibility, and the manufacturer provided equipment. Its result supports further investigation rather than a broad treatment claim.
A decision about fit, with evidence attached
Our editorial assessment is that Somnox remains a plausible relaxation aid with an unsettled sleep-efficacy record. Someone considering it should separate two questions: whether holding a moving companion feels appealing, and whether the expected benefit justifies buying one. We cannot answer the first from documentation, and the controlled studies do not settle the second for an individual.
The company itself says it has no research showing benefits for sleep apnea or restless legs syndrome. Its FAQ offers a 30-night return period subject to conditions, including return-shipping costs. Those terms deserve checking before purchase; a trial window is a way to assess personal fit, not scientific proof of effectiveness.